This Week in Gastroenterology — Jun 22, 2026

Welcome to This Week in Gastroenterology. This week we are covering eight notable papers spanning advanced risk-stratification models in colorectal and mucosal disease, emerging strategies in hepatology and liver transplantation, and cost-effective luminal interventions. Let's dive in.

We are seeing a global rise in early-onset colorectal and gastrointestinal cancers, demanding a better understanding of biological risk factors beyond chronological age. In Nature Medicine, researchers investigated how systemic and organ-specific biological aging relates to early-onset solid cancers among over 154,000 young adults from the United Kingdom Biobank [1]. They found that systemic aging, measured by a metric called PhenoAge, has risen across successive birth cohorts, showing a 23% standard deviation increase for individuals born between 1965 and 1974 compared to those born between 1950 and 1954. This accelerated biological aging was significantly associated with a higher risk of early-onset solid cancers, particularly gastrointestinal, lung, and uterine cancers, independent of genetic risk. When looking at organ-specific proteomics, the authors linked accelerated aging of adipose tissue specifically to a 60% increase in the risk of early-onset colorectal cancer. These findings, which were partially validated in over 10,000 participants from the United States All of Us Research Program, suggest that biological age gap assessments could help identify young adults at elevated risk for gastrointestinal malignancies.

This need to refine how we identify and manage colorectal cancer risk is also the focus of a compelling viewpoint published in The Lancet Gastroenterology & Hepatology [5]. The authors argue that our current post-polypectomy colonoscopy surveillance strategies are poorly balanced, placing a substantial burden on patients, healthcare budgets, and endoscopy capacity. They point out that many patients currently classified as high-risk under standard guidelines actually have a low absolute risk of developing colorectal cancer. This misclassification leads to significant overuse of surveillance colonoscopies. To address this, they call for a paradigm shift toward a comprehensive, risk-stratified framework. Instead of relying on historical data that often lacks quality indicators, clinical decisions should be guided by absolute colorectal cancer risk thresholds. For lower-risk individuals, we should incorporate less invasive triage approaches to optimize resource allocation and minimize unnecessary procedural risks.

Adding another layer to how individual biology interacts with environmental exposures to influence gastrointestinal health, a prospective cohort study of over 455,000 individuals published in Gut explores how alcohol consumption affects the risk of inflammatory bowel disease [7]. The relationship between alcohol and IBD has long been controversial, but this study suggests the answer lies in how an individual metabolizes acetaldehyde. The researchers constructed an acetaldehyde burden score based on genetic variants of alcohol dehydrogenase and aldehyde dehydrogenase. For individuals with a low acetaldehyde burden—meaning they generate acetaldehyde slowly and metabolize it rapidly—each standard deviation increase in red wine consumption, equivalent to about 60 grams of pure alcohol per week, was associated with a 20% reduced risk of Crohn's disease. However, for those with a high acetaldehyde burden, the same level of consumption was associated with a 38% increased risk of inflammatory bowel disease. These findings were supported by in vivo and in vitro experiments using mice and human-derived colonic organoids, which confirmed that modulating aldehyde dehydrogenase activity directly alters colitis outcomes. This highlights the clinical importance of considering genetic differences in alcohol metabolism when counseling patients on dietary and lifestyle modifications for inflammatory bowel disease prevention.

Moving to hepatology, we begin with a major clinical update in pediatric liver transplantation. The American Association for the Study of Liver Diseases, in collaboration with the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the American Society of Transplantation, has published an updated practice guideline in Hepatology on the evaluation of pediatric liver transplant candidates [3]. Replacing the previous 2014 guidelines, this comprehensive document outlines evidence-based recommendations for infants, children, and adolescents experiencing liver tumors, inborn errors of metabolism, and irreversible liver disease. The guideline provides clear, graded recommendations on indications, contraindications, pre-transplant assessment, and organ allocation strategies, aiming to optimize survival while maintaining clinical flexibility for individual patient scenarios.

In adult hepatology, genetic insights are also reshaping how we understand and treat cholestatic diseases. A review published in Gut highlights how the increasing availability of DNA sequencing is bridging the gap between rare, progressive pediatric syndromes and adult-onset cholestasis [6]. Severe pediatric conditions like progressive familial intrahepatic cholestasis, or PFIC, share a common genetic basis with more common adult-onset conditions, such as intrahepatic cholestasis of pregnancy, benign recurrent intrahepatic cholestasis, and low phospholipid-associated cholelithiasis. These adult conditions often involve functional variants in PFIC-associated genes, particularly ATP8B1, ABCB11, and ABCB4. Identifying these genetic variants is becoming highly clinically relevant due to the availability of intestinal bile acid transporter inhibitors, or IBAT inhibitors. These agents, which are highly effective for treating severe pruritus in pediatric PFIC, represent a promising genotype-specific treatment option for adult patients with later-onset cholestatic diseases who suffer from debilitating pruritus. Incorporating genetic screening into the evaluation of adult cholestasis can therefore directly guide personalized therapeutic decisions.

For patients with chronic viral hepatitis, understanding long-term prognosis is crucial for guiding monitoring and therapy. A longitudinal study published in Gut analyzed the clinical course of 565 patients with chronic hepatitis delta from the European D-SOLVE and hepatitis D virus 1000 consortia who were followed for at least three years [8]. Over a median follow-up of nearly five years, the cumulative incidence of progression to cirrhosis was approximately 14% at five years, while de-novo liver-related events occurred in about 11% of patients at five years. Multivariable analysis revealed that co-infection with hepatitis C virus and elevated baseline gamma-glutamyl transferase, or GGT, were significantly associated with the onset of cirrhosis. Furthermore, older age, elevated GGT, baseline cirrhosis, and detectable hepatitis D virus RNA were independent predictors of major liver-related events. Notably, the risk for liver-related events increased significantly once hepatitis D virus RNA levels reached 1,000 international units per milliliter or higher, whereas hepatitis B surface antigen levels did not correlate with disease progression. This emphasizes the importance of quantitative viral load monitoring in managing hepatitis delta.

In our final theme, we look at optimizing everyday clinical interventions in the endoscopy suite and the clinic. First, we examine the management of prophylactic pancreatic duct stents placed during endoscopic retrograde cholangiopancreatography, or ERCP, to prevent post-ERCP pancreatitis. While these stents are highly effective, the optimal duration they should remain in place has been unclear. A multicenter randomized controlled trial published in Clinical Gastroenterology and Hepatology compared a 2-week versus a 4-week stent retention strategy in 156 patients [2]. The investigators found that patients randomized to the 4-week retention group had a significantly lower need for endoscopic stent removal compared to the 2-week group, at roughly 7% versus 19%. This difference was driven by a higher rate of spontaneous stent dislodgment in the 4-week group, which reached over 92% compared to 81% in the 2-week group. Importantly, leaving the stent in place for 4 weeks did not increase the incidence of post-ERCP pancreatitis or other complications. This simple adjustment in clinical practice can spare a significant number of patients from undergoing an unnecessary repeat endoscopy.

Next, we turn to the management of recurrent Clostridioides difficile infection, where the clinical challenge often centers on balancing therapeutic efficacy with financial cost. A cost-effectiveness analysis published in The American Journal of Gastroenterology evaluated two Food and Drug Administration-approved microbiota-based therapies: oral fecal microbiota spores, live-brpk, and rectally administered fecal microbiota, live-jslm [4]. Using a decision-tree model from a United States payer perspective, researchers found that after a first recurrence of C. difficile, early initiation of both therapies was highly cost-effective compared to standard of care alone, coming in well below the standard willingness-to-pay threshold of 150,000 dollars per quality-adjusted life-year. However, after a second recurrence, the cost-effectiveness profiles diverged. The oral spore therapy remained cost-effective at approximately 54,000 dollars per quality-adjusted life-year, whereas the rectal microbiota therapy exceeded the willingness-to-pay threshold, costing over 171,000 dollars per quality-adjusted life-year. While head-to-head clinical trials are still needed, these findings suggest that integrating microbiota-restoration therapies earlier in the treatment pathway—specifically after the very first recurrence—offers the greatest clinical benefit at an acceptable cost.

If you only have time for one paper this week, make it the multicenter randomized controlled trial on pancreatic duct stent retention duration published in Clinical Gastroenterology and Hepatology [2]. This study provides clear, actionable evidence that extending the scheduled assessment for prophylactic stent retention from two to four weeks significantly increases spontaneous dislodgment and cuts the need for manual endoscopic removal by more than half, without compromising patient safety.

Here are the key takeaways from this week in Gastroenterology:

First, biological aging, particularly of adipose tissue, is associated with a rising risk of early-onset colorectal and solid gastrointestinal cancers in younger generations, suggesting a future role for biological age screening.

Second, extending prophylactic pancreatic duct stent retention to four weeks after ERCP significantly reduces the need for endoscopic removal via higher spontaneous dislodgment, with no increase in pancreatitis risk.

Third, microbiota-restoration therapies for recurrent Clostridioides difficile are most cost-effective when initiated early, specifically after the first recurrence rather than waiting for subsequent episodes.

Fourth, in patients with chronic hepatitis delta, close monitoring of viral load is essential, as the risk of major liver-related events increases significantly when hepatitis D virus RNA levels reach or exceed 1,000 international units per milliliter.

And finally, genetic testing for progressive familial intrahepatic cholestasis gene variants in adults with unexplained cholestasis can help identify candidates who may benefit from targeted therapies like intestinal bile acid transporter inhibitors.

That's your roundup for This Week in Gastroenterology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.